Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.
Website105 Piccadilly
London, W1J 7NJ
United Kingdom
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Biotech leader Kiniksa stock is poised to hit a new buy point after shares soared 25% in response to better-than-expected sales numbers.
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining. But the company has a plan.
Investors talking about KNSA also mention
What share of all stock conversation is about KNSA?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% +0 |
Of the messages about KNSA that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% 0 | 96.3% +1.36 | ||
| Bearish | — | — | 0% 0 | 3.7% -1.36 |
Of the messages about KNSA that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Technical Analysis | — | — | 39.57% | 28.91% | ||
| Announcements | — | — | 60.43% | 50.25% | ||
| Analysts | — | — | 0% | 8.74% | ||
| Earnings | — | — | 0% | 4.87% | ||
| Macro | — | — | 0% | 7.23% | ||
| Controversies | — | — | 0% | 0% |
Of the messages about KNSA, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | 100% | 85.67% | 73.09% | ||
| Newcomers | — | 0% | 14.33% | 26.91% |